# Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

> **NCT05132127** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 7 (actual)

## Conditions studied

- Cold Agglutinin Disease

## Interventions

- **DRUG:** sutimlimab

## Key facts

- **NCT ID:** NCT05132127
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132127, "Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05132127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*